115 related articles for article (PubMed ID: 9135503)
1. Benign and malignant thyroid lesions show instability at microsatellite loci.
Soares P; dos Santos NR; Seruca R; Lothe RA; Sobrinho-Simões M
Eur J Cancer; 1997 Feb; 33(2):293-6. PubMed ID: 9135503
[TBL] [Abstract][Full Text] [Related]
2. Microsatellite instability in thyroid tumours and tumour-like lesions.
Lazzereschi D; Palmirotta R; Ranieri A; Ottini L; Verì MC; Cama A; Cetta F; Nardi F; Colletta G; Mariani-Costantini R
Br J Cancer; 1999 Jan; 79(2):340-5. PubMed ID: 9888478
[TBL] [Abstract][Full Text] [Related]
3. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
4. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
[TBL] [Abstract][Full Text] [Related]
5. [Expression of BRAF V600E mutation in different thyroid lesions].
Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
[TBL] [Abstract][Full Text] [Related]
6. [Loss of heterozygosity on chromosome 3p in thyroid tumors].
Hu MJ; Xu HD; Zhou R; Li XF; Zhang HY
Zhonghua Bing Li Xue Za Zhi; 2008 May; 37(5):305-8. PubMed ID: 18956647
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Ras mutations in thyroid neoplasia.
Esapa CT; Johnson SJ; Kendall-Taylor P; Lennard TW; Harris PE
Clin Endocrinol (Oxf); 1999 Apr; 50(4):529-35. PubMed ID: 10468914
[TBL] [Abstract][Full Text] [Related]
8. Fetal adenomas and minimally invasive follicular carcinomas of the thyroid frequently display a triploid or near triploid DNA pattern.
Castro P; Sansonetty F; Soares P; Dias A; Sobrinho-Simões M
Virchows Arch; 2001 Apr; 438(4):336-42. PubMed ID: 11355166
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial D-Loop instability in thyroid tumours is not a marker of malignancy.
Máximo V; Lima J; Soares P; Botelho T; Gomes L; Sobrinho-Simões M
Mitochondrion; 2005 Oct; 5(5):333-40. PubMed ID: 16183030
[TBL] [Abstract][Full Text] [Related]
10. Flow cytometric DNA measurement in benign and malignant human thyroid tissues.
Mizukami Y; Nonomura A; Michigishi T; Kosaka T; Noguchi M; Nakamura S; Hashimoto T
Anticancer Res; 1992; 12(6B):2213-7. PubMed ID: 1295468
[TBL] [Abstract][Full Text] [Related]
11. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours.
Sheu SY; Grabellus F; Schwertheim S; Worm K; Broecker-Preuss M; Schmid KW
Br J Cancer; 2010 Jan; 102(2):376-82. PubMed ID: 20029416
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
13. Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours.
Banito A; Pinto AE; Espadinha C; Marques AR; Leite V
Clin Endocrinol (Oxf); 2007 Nov; 67(5):706-11. PubMed ID: 17651453
[TBL] [Abstract][Full Text] [Related]
14. Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours.
Ruschenburg I; Vollheim B; Stachura J; Cordon-Cardo C; Korabiowska M
Anticancer Res; 2006; 26(3A):2107-12. PubMed ID: 16827152
[TBL] [Abstract][Full Text] [Related]
15. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens.
Giordano TJ; Beaudenon-Huibregtse S; Shinde R; Langfield L; Vinco M; Laosinchai-Wolf W; Labourier E
Hum Pathol; 2014 Jul; 45(7):1339-47. PubMed ID: 24830619
[TBL] [Abstract][Full Text] [Related]
16. Loss of heterozygosity in follicular and papillary thyroid carcinomas.
Rodrigues-Serpa A; Catarino A; Soares J
Cancer Genet Cytogenet; 2003 Feb; 141(1):26-31. PubMed ID: 12581895
[TBL] [Abstract][Full Text] [Related]
17. Assessment of microsatellite instability in bladder and thyroid malignancies.
Vaish M; Mishra SK; Mandhani A; Mittal RD; Mittal B
Teratog Carcinog Mutagen; 2003; Suppl 1():255-65. PubMed ID: 12616616
[TBL] [Abstract][Full Text] [Related]
18. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas.
Manenti G; Pilotti S; Re FC; Della Porta G; Pierotti MA
Eur J Cancer; 1994; 30A(7):987-93. PubMed ID: 7946598
[TBL] [Abstract][Full Text] [Related]
19. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors.
Puskas LG; Juhasz F; Zarva A; Hackler L; Farid NR
Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(2):177-86. PubMed ID: 16171553
[TBL] [Abstract][Full Text] [Related]
20. Aberrant deoxyribonucleic acid methylation in human thyroid tumors.
Matsuo K; Tang SH; Zeki K; Gutman RA; Fagin JA
J Clin Endocrinol Metab; 1993 Oct; 77(4):991-5. PubMed ID: 7691865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
